By VETTAPHARMA reporter: The U.S. Food and Drug Administration has approved Optune Pax, a first-of-its-kind medical device for the treatment of adult patients with locally advanced pancreatic cancer — marking a milestone in cancer care after years of limited therapeutic advances.
Developed by Novocure, Optune Pax is a portable, non-invasive device that delivers tumor-treating fields (TTFields) — alternating electrical fields applied to the abdomen via externally attached insulated adhesive patches. These fields disrupt the rapid cell division typical of cancer cells while sparing healthy tissue, offering a fundamentally different mechanism compared to conventional therapies.
The device is designed to be worn continuously, with the generator carried in a specially designed bag so patients can undergo treatment while maintaining daily activities. Patients are trained on device use, including how to place the adhesive patches, replace transducer arrays at least twice weekly, recharge batteries and connect to external power when needed.
Optune Pax received approval under the FDA’s premarket approval (PMA) pathway, the agency’s most stringent review process for medical devices. Approval was based on pivotal clinical data demonstrating that adding TTFields to standard chemotherapy regimens — gemcitabine and nab-paclitaxel — improved overall survival by approximately two months compared to chemotherapy alone in adults with locally advanced pancreatic cancer.
Common device-related risks observed in the pivotal study included localized skin reactions at the patch sites; however, no other new safety concerns emerged during the evaluation.
Pancreatic cancer is one of the most difficult cancers to treat; according to data from the National Cancer Institute included in the FDA announcement, approximately 67,440 new cases and 51,980 deaths were expected in the U.S. in 2025 alone. Although pancreatic cancer accounts for about 3.3 % of all new cancer diagnoses, it contributes a disproportionately high share of cancer-related deaths due to late detection and limited treatment options.
FDA Commissioner Marty Makary, M.D., M.P.H., emphasised that patients and clinicians have long awaited new tools against this aggressive disease. The approval is also aligned with the FDA’s Home as a Health Care Hub Initiative, a program aimed at enabling patient-centric care with innovative medical technologies that can be used outside traditional clinical settings.
The Optune Pax device was granted Breakthrough Device designation by the FDA in December 2024 — a status intended to expedite the development and review of medical technologies that have the potential to offer more effective treatments for life-threatening diseases.
Source credit:
- U.S. Food and Drug Administration. (2026, February 12). FDA approves first-of-its-kind device to treat pancreatic cancer. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer?utm_medium=email&utm_source=govdelivery
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
